Free Trial
NASDAQ:DRUG

Bright Minds Biosciences 2/13/2025 Earnings Report

Bright Minds Biosciences logo
$32.94 -0.48 (-1.44%)
As of 10:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bright Minds Biosciences EPS Results

Actual EPS
$0.01
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.24
One Year Ago EPS
N/A

Bright Minds Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bright Minds Biosciences Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bright Minds Biosciences' next earnings date is estimated for Wednesday, May 21, 2025, based on past reporting schedules.

Conference Call Resources

Bright Minds Biosciences Earnings Headlines

Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
Bright Minds Biosciences expands Scientific Advisory Board
Bright Minds Biosciences (DRUG) Receives a New Rating from Piper Sandler
See More Bright Minds Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bright Minds Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bright Minds Biosciences and other key companies, straight to your email.

About Bright Minds Biosciences

Bright Minds Biosciences (NASDAQ:DRUG), a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

View Bright Minds Biosciences Profile

More Earnings Resources from MarketBeat